2024 Targeted Therapies for Lung Cancer (TTLC) - Abstracts & Posters-PP01.23 Paydary

PP01.23 Paydary - Abstract

Pdf Summary

The document discusses the correlation between polypharmacy, drug-drug interactions, drug-substance interactions, and toxicities among patients with non-small cell lung cancer (NSCLC) taking Tyrosine Kinase Inhibitors (TKI). Conducted at Rush University Medical Center, the retrospective analysis involved 153 patients taking TKIs from 2012 to 2022. Results showed 75.6% of patients experienced toxicities, with those taking more medications being more susceptible. Cannabis product use was linked to increased toxicity risk, while the use of antacids was inversely associated with toxicities among patients on erlotinib. Clinically significant drug-drug interactions were identified in 15.6% of cases, with antacids being the most common cause. The study suggests that a significant portion of toxicities associated with TKIs could be avoided by managing drug-drug and substance interactions. The findings emphasize the importance of addressing polypharmacy and substance use in patients with NSCLC to reduce targeted toxicities. Future studies are needed to further explore these interactions and their impact on treatment outcomes in this patient population.

Keywords

polypharmacy

drug-drug interactions

drug-substance interactions

toxicities

non-small cell lung cancer

Tyrosine Kinase Inhibitors

retrospective analysis

Rush University Medical Center

cannabis product use

antacids